ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1451

Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1297

Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.

(1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1510

Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1166

Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1602

Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis

(1592–1611) Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1042

Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after

(1038–1054) Health Services Research Poster II

10:30AM-12:30PM: Abstract Number: 1498

Both Race and Socioeconomic Status Affect Mortality in SLE

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1112

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 0996

Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1264

Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1050

Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care

(1038–1054) Health Services Research Poster II

10:30AM-12:30PM: Abstract Number: 1085

Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1243

Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1394

Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1477

Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

«Previous Page
1
…
7
8
9
10
11
…
58
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].